OncoMatch/Clinical Trials/NCT06380816
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Is NCT06380816 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies UCB4594 for advanced solid tumours.
Treatment: UCB4594 — This clinical trial is looking at UCB4594. This is the first time the drug is being tested in humans. UCB4594 is a type of drug called a monoclonal antibody. It has been designed to work by targeting a protein called human leucocyte antigen G (HLA-G) that is found in high levels on some cancer cells. By attaching itself to this protein it may help the immune system to attack and kill the cancer cells. The four main aims of the clinical trial are to find out: 1. The best dose of UCB4594 that can be given safely to participants in the trial. 2. What the side effects of UCB4594 are and how they can be managed. 3. What happens to UCB4594 inside the body and how it affects cancer cells. 4. Whether UCB4594 can cause cancer to shrink.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Renal Cell Carcinoma
Esophageal Carcinoma
Gastrointestinal Stromal Tumor
Gastric Cancer
Cervical Cancer
Ovarian Cancer
Pancreatic Cancer
Biomarker criteria
Required: HLA-G overexpression (high levels (as reported in the literature))
Tumour types which have shown high levels of human HLA-G expression (as reported in the literature)
Disease stage
Metastatic disease required
advanced solid tumours (as specified below), refractory to conventional treatment, or for which no conventional therapy is considered appropriate by the Investigator or is declined by the participant
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: conventional treatment
refractory to conventional treatment, or for which no conventional therapy is considered appropriate by the Investigator or is declined by the participant
Cannot have received: HLA-G, ILT2 or ILT4-targeting drug
Prior treatment with HLA-G, immunoglobulin-like transcript (ILT)2 or ILT4-targeting drug
Lab requirements
Blood counts
haematological indices within defined ranges
Kidney function
biochemical indices within defined ranges
Liver function
biochemical indices within defined ranges
Haematological and biochemical indices within defined ranges. These measurements should be performed to confirm the patient's eligibility to participate in the trial
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify